A step ahead in the management of HFmrEF and HFpEF - PACE-CME

A step ahead in the management of HFmrEF and HFpEF

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
ESC 2020
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
- Prof. Freek Verheugt, MD
Incredible consistency between two SGLT2i trials in HFrEF
Incredible consistency between two SGLT2i trials in HFrEF
ESC 2020
Incredible consistency between two SGLT2i trials in HFrEF
- Milton Packer, MD
Advantages of the digital 2020 ESC Congress
Advantages of the digital 2020 ESC Congress
ESC 2020
Advantages of the digital 2020 ESC Congress
- Prof. Barbara Casadei, MD
Colchicine reduces primary outcome in chronic coronary disease
Colchicine reduces primary outcome in chronic coronary disease
ESC 2020
Colchicine reduces primary outcome in chronic coronary disease
- Mark Nidorf, MD